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Abstract
Tumor budding has been reported to be an independent prognostic factor in pancreatic ductal adenocarcinoma (PDAC). Its use in
daily diagnostics would improve the prognostic stratification of patients. We performed a multicenter interobserver study to test
various budding assessment methods for their reproducibility. Two serial sections of 50 resected, treatment-naïve PDACs were
stained for Hematoxylin and Eosin (H&E) and pancytokeratin. Tumor budding was scored by independent observers at five
participating centers in Switzerland, Germany, and Canada. Pathologists assessed tumor budding on a digital platform comparing
H&E with pancytokeratin staining in 10 high-power fields (10HPF) and one HPF hotspot (1HPF). Additionally, tumor budding
was assessed in one H&E hotspot at × 20 magnification, as suggested by the International Tumor Budding Consensus
Conference (ITBCC). Correlation coefficients for bud counts between centers ranged from r = 0.58648 to r = 0.78641 for
H&E and from r = 0.69288 to r = 0.81764 for pancytokeratin. The highest interobserver agreement across all centers was
observed for pancytokeratin 10HPFs (ICC = 0.6). ICC values were 0.49, 0.48, 0.41, and 0.4 for H&E in 1HPF hotspot, H&E in
10HPFs, pancytokeratin in 1HPF, and H&E in one hotspot at ×20, respectively (ITBCC method). This interobserver study
reveals a range between moderately poor to moderate agreement levels between pathologists for the different tumor budding
assessment methods in PDAC. Acceptable levels of agreement were reached with the pancytokeratin 10HPF method, which can
thus be recommended for the assessment of tumor budding in PDAC resection specimens. To improve the levels of interobserver
agreement, the implementation of machine learning applications should be considered.
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Introduction
Pancreatic adenocarcinoma (PDAC) is a major cause of
cancer-associated mortality in Western countries and it is ex-
pected to emerge as the second leading cause of cancer-related
death by 2030 [1]. Surgical resection with curative intent is
currently considered to be the only chance for improving sur-
vival [2, 3]. Recent advances in the multimodal management
of patients with PDAC have improved the 5-year overall sur-
vival rates up to 20–40% following oncologic resection for
PDAC [4, 5]. Despite these significant advances in the treat-
ment of PDAC, tumor recurrence following radical resection
remains high thus limiting long-term survival [6].
Furthermore, PDAC is a highly heterogeneous disease and
even patients with the same TNM stage have different out-
comes [7]. Thus, the identification of biomarkers that would
enable a more accurate prediction of the tumor biology of
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PDAC is necessary, in order to optimize modern individual-
ized patient management.
Tumor buds are defined as single or small groups of up to
four carcinoma cells growing detached from the main tumor
[8] and have been shown to display features of epithelial-to-
mesenchymal transition as well as stem cell features [9–12].
Increased numbers of tumor buds have been correlated with
adverse clinicopathological features, such as diminished
progression-free and overall survival in many gastrointestinal
cancers [13]. Since tumor budding has been recognized as a
biomarker with prognostic significance in pancreatic ductal
adenocarcinoma (PDAC) [14–17], including information on
a parameter such as tumor budding into the histopathology
reports would supply an additional useful tool in adjusting
personalized patient risk stratification. Thus, information re-
garding tumor budding could provide a prognostic indicator to
help in the identification of high-risk patients who would prof-
it from a more intensified tumor surveillance following onco-
logic resection with curative intent. However, although tumor
budding is considered a promising and/or additional prognos-
tic factor for other tumor entities, such as colorectal cancer
[18], it is still not included in any classification or protocol
for PDAC and it is not recommended by any society, includ-
ing the College of American Pathologists.
One of the reasons that might explain the reluctance to
report tumor budding in PDAC is the lack of a unified, stan-
dardized, and reproducible scoring method. To add confusion,
several methods have been used so far for the evaluation of
tumor budding, encompassing semiquantitative or quantita-
tive methods with different cut-offs [19–21]. Moreover, some
studies assess tumor budding on hematoxylin and eosin
(H&E)–stained slides while others use immunohistochemical
staining for pancytokeratin, which on one hand greatly in-
creases the number of identifiable tumor buds, but on the other
hand, also increases the turnaround times and expenses of
specimen evaluation and reporting [22]. More recently, the
International Tumor Budding Consensus Conference
(ITBCC) 2016 for colorectal cancer proposed the assessment
of one hotspot at × 20 magnification on H&E-stained slides as
a standardized and easily applicable method to report tumor
budding in colorectal cancer [23], which has been validated
and reproduced also in PDAC [17, 24]. Another important
aspect that hampers the clinical use of tumor budding in
PDAC is the issue of interobserver variability. So far, a num-
ber of studies have addressed the interobserver variability of
tumor budding assessment in colorectal cancer and reported
low to acceptable levels of agreement [22, 25, 26], while cur-
rently, studies examining the multi-institutional interobserver
variability for the various reported tumor budding assessment
methods do not exist for PDAC.
The challenge thus lies in the identification of the most
reproducible method to assess tumor budding, to help include
this information into daily diagnostic practice. We performed
a multicenter interobserver study between pathologists at five
participating, high-volume diagnostic centers in Switzerland,
Germany, and Canada with the objective to test various tumor
budding assessment methods in PDAC for their reproducibil-
ity. In this, we compared five different methods of evaluation,
including the assessment of 10 high-power fields (10HPF) and
of one HPF hotspot (1HPF) both using H&E and
pancytokeratin staining, as well as the evaluation of one
H&E hotspot at × 20 magnification as suggested by ITBCC
[23].
Material and methods
Patients and tissue blocks
Out of routinely assessed PDAC resection specimens from
treatment-naïve patients operated at the Insel University
Hospital, Bern, Switzerland, and at University Clinic
Cologne, 50 PDACs TNM stage I–III, were randomly select-
ed for the present study. All tumor slides of each case (mini-
mum of one tumor block per 1 centimeter of tumor diameter),
were reviewed by an experienced pathologist (either PL or
EK). One representative tumor block from the center of the
tumor containing pancreatic tissue mostly occupied by carci-
noma was selected for further processing. Two 4-μm-thick
serial sections were cut: one was stained with H&E while
the other underwent immunohistochemistry for the
pancytokeratin marker AE1/AE3 (Dako, mouse monoclonal,
1:200) using a Leica Bond III instrument. The evaluation was
performed after anonymization following all the ethical guide-
lines required by all institutions with which all the authors are
affiliated. The clinicopathological characteristics of the pa-
tients are summarized in Suppl. Table 1. The study design is
depicted in Suppl. Figure S1. The Ethics Commission of the
Canton of Bern has approved the use of patients’ tissue for the
implementation of this project (2019-02212). Informed con-
sent is available for all patients.
Evaluation of tumor budding
Tumor budding was defined as single cells or clusters of up to
four tumor cells present at any tumor area. For pancytokeratin-
stained slides, tumor buds needed to show clear cytoplasmic
cytokeratin reactivity and a nucleus. Cytoplasmic
pseudofragments or areas of necrosis were excluded.
Digital pathology and selection of areas for counting
All slides (n = 2 × 50 = 100) were scanned and digitalized in a
3DHistech P250 scanner and a separate case center account
for each participating pathologist was created. The slides were
evaluated by virtual microscopy using the Case Viewer
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software (Case Viewer 3DHISTECH_Ltd Version
2.2.0.85100). Observers were blinded to clinicopathological
data and patient information and scored tumor budding in
H&E and pancytokeratin-stained slides independently.
Areas of tumor budding were first identified using low
power magnification. Standardized counting areas
representing one field at × 40 magnification representing 1
high-power field (1HPF; field diameter 600 μm, area 282
μm2) and one field at × 20 magnification (field diameter
1100 μm, area 950 μm2) were simulated using fixed-size an-
notations and placed by each observer individually in areas of
highest budding density (Fig. 1). Tumor buds were then
counted in a total of 10 fields at × 40 magnification (10
HPFs method) and in one densest hotspot at × 40 magnifica-
tion (1HPF method), both in H&E and pancytokeratin. Then,
tumor budding was counted in one hotspot at × 20 magnifica-
tion in H&E staining (area 950 μm2). The number of tumor
buds counted in that area was divided by 1.21 to obtain the
number of buds in an area of 785μm2 according to the ITBCC
method [23]. All counts were recorded in an excel file. Each
participating center provided one single excel file with the
budding counts. The values were compared for agreement
across the five participating centers. Pathologists of institute
1, institute 3, and institute 5 had previous experience, while
Fig. 1 Tumor budding
assessment on digital slides:
HPFs of standardized size (× 40,
field diameter 600 μm, area 282
μm2) and at × 20 (field diameter
1100 μm, area 950 μm2) were
simulated using a fixed size
annotation which was placed by
each observer independently in
areas of highest tumor budding
density. The average number of
tumor buds counted on H&E- and
pancytokeratin-stained slides was
calculated and compared for
agreement across centers.
Overview of 10 HPFs on H&E
(a)-and pancytokeratin (b)-stained
slides. Higher magnification of
1HPF (× 40 magnification; c) and
at × 20 magnification (d) on an
H&E-stained slide
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pathologists of institute 2 and institute 4 had no previous ex-
perience in the evaluation of tumor budding in pancreatic
cancer.
Statistics
Descriptive statistics were carried out on tumor budding
scores. In a first step, Pearson’s correlation coefficient (r)
was used to determine the strength of the linear relationship
between observers’ values. Then to determine the interobserv-
er variability, the intraclass correlation coefficient (ICC) was
used. The ICC may be interpreted similarly to the Kappa with
values closer to 1.0 indicating stronger agreement.
Results
Comparison between pancytokeratin and H&E counts
across the participating centers
Tumor budding was scored by independent observers at five
participating centers in Switzerland, Germany, and Canada,
on H&E-stained slides and matched pancytokeratin (AE1/
AE3)-stained slides of 50 PDAC cases. Representative images
of the PDAC slides with the annotations (H&E and
pancytokeratin) are depicted in Fig. 1.
Average tumor budding counts across centers ranged from
7 to 11.6 buds using the 10HPF method on pancytokeratin-
stained slides (median: 8.7). These values were on average
significantly higher than with the 10HPF method on H&E
slides, which ranged from 2.4 to 7 buds (median: 4.6;
Table 1).
A similar trend was observed using the 1HPF hotspot
method. The single densest 1HPF containing tumor buds on
a pancytokeratin stain ranged from 14.9 to 28.7 (median: 16.9)
in comparison to a range from 6.8 to 12.5 buds on H&E
(median: 9.1). Again, on the pancytokeratin stain, significant-
ly more tumor buds were identified in comparison to H&E.
The average number of tumor buds across centers ranged from
11.6 to 18.9 when scoring tumor buds in 1 hotspot of an H&E
stained slide at × 20 (median: 13.3; Table 1).
Correlation of tumor budding counts between centers
A correlation matrix was performed in order to visualize the
relationship between tumor budding scores across all centers
(Suppl. Figure S2). Each center was compared to the four
others.
For H&E-stained slides, assessed using the 10HPFmethod,
correlation coefficients ranged from r ≤ 0.39 to r ≤ 0.84, with
an average of r = 0.76. The 1HPF method for H&E slides
performed similarly; the correlations had values of 0.48 to
0.85 and an overall r of 0.71. For pancytokeratin assessment
of tumor budding using the 10HPF approach, medium to
strong correlations were found with values of 0.51 ≤ r ≤
0.84 and an average overall r = 0.78. 1HPF in pancytokeratin
staining performed worse with a range of values from 0.11 to
0.81 and an overall correlation coefficient of 0.50. The corre-
lations of tumor budding counts observed between centers for
the ITBCC scoring method ranged from 0.16 to 0.87 with an
average r = 0.55. Correlation coefficients for the tumor bud-
ding categories (BD1, BD2, and BD3) according to the
ITBCC method [23, 24] ranged between 0.1 and 0.78 with
an average r = 0.44. The best correlation, especially for the
ITBCC method (both for buds counts and budding catego-
ries), was observed between institutes 1 and 3 (both had
previous experience on the assessment of tumor budding by
this and other methods; Suppl. Tables 2 and 3).
Table 1 Descriptive statistics on tumor budding by institute and
evaluation method
Scoring method Institute Mean Median Min Max
H&E 10 HPFs 1 5.0 3.6 0 22.6
2 7.0 6.6 1.5 17.0
3 5.5 4.6 0.4 25.
4 2.4 1.3 0 14.7
5 6.0 4.5 0.7 20.7
All 5.1 4.6 0.8 17.9
Pancytokeratin 10 HPFs 1 8.5 6.9 0 54.4
2 11.3 10.4 3.2 26.2
3 9.8 8.9 0.4 38.8
4 7.0 5.5 0.3 28.7
5 11.6 8.1 2.3 58
All 9.7 8.7 2.9 34.7
H&E 1 HPF 1 9.9 8.0 0 43.0
2 11.5 11. 2.0 30.0
3 9.7 8.0 1.0 44.0
4 6.8 4.0 0 42.0
5 12.5 10.0 4.0 44.0
All 10.1 9.1 1.4 36.6
Pancytokeratin 1 HPF 1 14.9 12.0 0 73.0
2 20.9 21.0 8.0 42.0
3 17.3 15.0 1.0 58.0
4 15.4 13.0 1.0 62.0
5 28.7 22.0 5.0 152.0
All 19.4 16.9 7.0 66.0
H&E 1 hotspot 20xITBCC 1 13.1 11.0 0 73.0
2 16.3 14.5 4.0 35.0
3 14.7 11.0 1.0 57.0
4 11.6 9.0 0 35
5 18.9 14.0 3.0 62
All 14.5 13.3 4.6 42.4
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Interobserver agreement of tumor budding counts
Correlation coefficients as a measure of linear relationship do
not represent interobserver agreement. Therefore, to assess the
agreement across all centers, the ICC values were calculated.
In descending order, ICC values were 0.6, 0.49, 0.48, 0.41,
and 0.4 for pancytokeratin in 10HPF method, H&E in 1HPF
method, H&E in 10HPF method, and pancytokeratin in 1HPF
method and ITBCC method (one hotspot H&E at × 20) re-
spectively (Table 2). A graphic representation of the mean
numbers of tumor buds by each evaluation method across all
five institutes is shown in Fig. 2.
Discussion
Several factors have been identified to be associated with di-
minished disease-free survival of the patients after resection of
pancreatic cancer including high tumor stage, lymph node
metastases [27], tumor involvement of the resection margins
[28], and last but not least tumor budding, which has been
found to add independent prognostic information [14–17].
All these factors are regularly included in the histopathology
reports except tumor budding, which is still missing in most
reports of resection specimens of treatment-naïve PDACs.
Including information on tumor budding would greatly im-
prove the prognostic stratification of PDAC patients, taking
into consideration the heterogeneity of PDAC tumors and the
lack of parameters other than TNM that are able to provide
such strong and independent prognostic information upon
histomorphologic evaluation [14–17]. There can be several
reasons for the reluctance to report tumor budding, one major
issue being related to the current lack of consensus concerning
the optimal evaluation method of tumor budding in PDAC
that underlines the need for a standardized and reproducible
scoring system.
We undertook an interobserver study in which we com-
pared different methods for the evaluation of tumor budding
[21, 23, 29] for their reliability, reproducibility, and applica-
bility. These methods and especially the 10HPFs (either by
pancytokeratin or by H&E) and the ITBCCmethod were cho-
sen because they have already been used to prove the prog-
nostic utility of tumor budding in large series of PDACs
[14–17, 24]. By performing this study, we were confronted
with all the issues related to such an evaluation, the most
important of which will be briefly addressed in the following
paragraphs.
One important issue is the selection of the most topograph-
ically suitable tumor area to evaluate the tumor buds.
Concerning PDAC, many factors support the fact that the
evaluation can actually take place across the whole tumor
area, independent of the topographic location within the tumor
(intratumorally or at the invasive front). Indeed, in PDAC
resection specimens, the distinction between intratumoral
(i.e., within the main tumor bulk) and peritumoral budding
(i.e., at the invasive front) is not always clear, and the borders
between them are often blurred. Care has to be taken, howev-
er, to distinguish tumor budding from poor differentiation, as
tumor budding differs from the tumor grade. Indeed, for the
evaluation of tumor grade, several morphologic factors, such
as the proportion of tumor gland forming component, mucin
production by the tumor cells, the number of mitoses, and
nuclear polymorphism, have to be considered [30]. Tumor
budding on the other hand is defined as the presence of single
cells or clusters of up to four neoplastic cells in a tumor area
and although it is more pronounced in poorly differentiated
tumors and has been found to correlate with tumor grade [17],
it can also be found in better-differentiated carcinomas.
Moreover, high-grade tumor budding was proved to be an
independent adverse prognostic factor in PDAC, also when
tumor grade was considered in the multivariate analysis [15].
Another factor that could primarily affect the reproducibil-
ity of tumor budding scoring is the different levels of experi-
ence among pathologists [25, 26]. Therefore, care was taken
so that pathologists from centers with both previous and no
previous experience in the evaluation of tumor budding
should participate in this study. Indeed, interobserver agree-
ment was higher among pathologists with previous experience
for almost all methods, with only the pancytokeratin 10HPF
method showing an acceptable overall interobserver agree-
ment, independently of the experience level of the pathologist
who performed the scoring. Especially concerning the ITBCC
method, which has been found to represent a very good and
cost-effective tool for the assessment of tumor budding in
pancreatic cancer [24], a high interobserver agreement was
observed only among pathologists with previous experience
on assessing tumor budding. This on another note signifies
that practice can improve the rates of interobserver agreement
for all methods and for the ITBCC method in particular.
A further frequently addressed issue when it comes to the
most suitable scoring method is the question about the neces-
sity to perform pancytokeratin staining for the evaluation of
the tumor buds. It is true that in almost all studies, including
the present one, pancytokeratin staining has been proved su-
perior to H&E concerning the identification of tumor buds,









H&E 10 HPFs 0.48
Pancytokeratin 10 HPFs 0.6
H&E 1 HPF 0.49
Pancytokeratin 1 HPF 0.41
ITBCC 0.40
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compared with H&E [22]. Pancytokeratin staining helps, for
example, distinguishing tumor buds from activated fibroblasts
or small clusters of neuroendocrine cells that may be encoun-
tered among the tumor infiltrates. However, the application of
an immunohistochemical staining slightly increases the ex-
penses and the time needed for the evaluation and reporting
of the specimen. For this reason, we assessed tumor buds by
evaluating both pancytokeratin and H&E stained slides and by
applying different assessment methods. Indeed, the interob-
server agreement after the evaluation of 10 HPFs in
pancytokeratin-stained slides achieved the best ICC value
(ICC = 0.6) among all participating pathologists. When apply-
ing the 1HPF method in pancytokeratin-stained slides, the
distribution of scores between centers was considerably more
dispersed and the interobserver agreement dropped to 0.41,
achieving similar ICC values to that of H&E scoring methods
(0.40 to 0.49). This suggests that pancytokeratin staining per-
forms better than H&E only after evaluation of a considerably
greater number of high-power fields. Moreover, our results
show that the ITBCC method still holds value, but only
among pathologists with previous experience in tumor bud-
ding evaluation. Therefore, and after taking into consideration
important factors such as reproducibility and reliability, the
pancytokeratin 10HPF method seems to be the method of
choice for the assessment of tumor budding in pancreatic can-
cer resection specimens from non-neoadjuvantly treated
patients. For the assessment of tumor budding in specimens
with only limited amount of evaluable tumor material, such as
small invasive carcinoma foci in a predominantly non-
invasive cystic pancreatic neoplasm, encompassing pT1 car-
cinomas, the evaluation of 1 HPF in H&E-stained slides,
which achieved the second best ICC value in our study
(0.49), would be more suitable. Assessing tumor budding in
PDAC resection specimens from neoadjuvantly treated pa-
tients cannot be recommended at this point and further studies
are required for its inclusion, in comparison with stage, regres-
sion grading, and outcome.
The present interobserver study on tumor budding evalua-
tion in pancreatic cancer reached only moderate levels of
agreement among participating institutes. This is in keeping
with other previous interobserver studies on tumor budding
assessment in colorectal cancer [25, 26, 31] and can be attrib-
uted to various reasons, including the stain used (H&E versus
pancytokeratin) and the experience and/or expertise of the
pathologists, as discussed in the previous paragraphs. One
further parameter is that this and other studies include the
use of digital images for the evaluation of tumor budding, in
contrast to the microscopic assessment still used for routine
diagnostics by most pathologists. Although digital pathology
is becoming increasingly part of our lives, the experience
levels of pathologists in evaluating digital slides are variable,
contributing to the suboptimal interobserver agreement.
Fig. 2 Graphic representation of the mean counts of identified tumor buds across all five institutes for the five evaluation methods
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Recently, an effort is being made to overcome these difficul-
ties by optimizing computer-aided detection systems, which
by employing deep learning algorithms would be capable of
recognizing complex structures such as tumor buds [31].
Finally, after conducting a multi-institutional, interobserver
study using five different scoring methods of tumor budding
and taking into account all the above-discussed issues, we can
deduce that only the pancytokeratin 10 HPF scoring method
achieved acceptable levels of interobserver agreement and
thus can be recommended for the assessment of tumor bud-
ding in PDAC resection specimens from treatment-naïve pa-
tients. To improve the levels of interobserver agreement, the
implementation of machine learning applications should be
considered.
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